To: Chuca Marsh who wrote (2863 ) 4/18/2002 7:20:27 AM From: Chuca Marsh Read Replies (1) | Respond to of 5409 Hey NEWS LAMP and I posted POST 5600 and it will not show LOL: 18 Apr 2002 7:16 AM EDT Msg. 5600 of 5600 Me and wife just looked at CEPT 10 yr chart we bot at $9 befor the apps and sold at $23; it is $61 now. This was an inquiry SHE had after me telling her about LAMP FDA approval. Think on it/ Chucka Disclaimers: chuckapublicrelations.com (( New Clients wanted -LOL, cheap value added companies))By: rayk $$ 18 Apr 2002, 07:15 AM EDT Msg. 5599 of 5600 April 18, 2002 07:01 Permission to Market LAM IPM(TM) Wound Gel Received From the FDA By LAM Pharmaceutical Corporation Jump to first matched term LEWISTON, N.Y., April 18 /PRNewswire-FirstCall/ -- LAM Pharmaceutical, Corp. (OTC Bulletin Board: LAMP; FRANKFURT STOCK EXCHANGE: LAM; BERLIN: LAM), lampharm.com , is pleased to announce that the Company has received permission to market its proprietary, patented wound product -- LAM IPM(TM) Wound Gel*, pursuant to the Section 510(k), (FDA assigned number K020325). The letter from the FDA, the Department of Health & Human Services, Division of General, Restorative and Neurological Devices, Office of Device Evaluation, Centre for Devices and Radiological Health, was dated April 15, 2002 and was received by the Company on April 17, 2002. LAM IPM(TM) Wound Gel has demonstrated in human trials an 88.0% rate of effectiveness in creating the necessary environment for wound healing of refractory (hard to heal) leg and foot ulcers. The incidence of these types of ulcers is increasing rapidly, as the baby boom generation ages and people live longer. Last year, 26 million ulcers were reported in the United States alone, of which approximately 6 million have been estimated as being chronic, difficult to heal and requiring thousands of dollars in total treatment costs. Alan Drizen, Chief Executive Officer of LAM stated, "I am most gratified to receive the permission to market LAM IPM(TM) Wound Gel, especially since it comes earlier than anticipated. While most important to LAM by itself, the approval of this significant product for sale sets the stage for commercialization of other major products in our portfolio." Joseph Slechta, LAM President and Chief Operating Officer added, "Now that we have received permission to market our IPM(TM) wound product, we will immediately proceed with its introduction to market. The target date for the product launch has been set for June 3, 2002." "L.A.M. IPM(TM) WOUND GEL" L.A.M. IPM(TM) Wound Gel is a clear, viscous, odorless, aqueous gel composed principally of sodium hyaluronate, a derivative salt of Hyaluronic acid. Hyaluronic acid is a naturally occurring molecule found in various parts of the body. Hyaluronic acid used in L.A.M. IPM(TM) Wound Gel is derived from avian sources. The gel has demonstrated to be of value in the management of certain skin ulcers and wounds where maintaining a moist environment is supportive of the healing process. In human skin hyaluronic acid is involved in such important biological functions as tissue hydration and proteoglycan organization (formation of proteins and sugars). • Great Deals on Hundreds of Cruises • QCharts: Real-time trading software, $80/mo • Free portfolios with 75 symbols,news and more REACT TO THIS MEMBER • Add to favorite members (formerly membermark) • Ignore/Hide this poster in all boards • Report TOS violation Reply to msg. Post new msg. Email this msg. « Message list Add to favorit Reply to msg. Post new msg. Email this msg. By: carefull99 $$$ 18 Apr 2002, 07:16 AM EDT Msg. 5600 of 5600 (This msg. is a reply to 5598 by ipm10.) ipm10 lets hope it's a chain not a rope. • Great Deals on Hundreds of Cruises • QCharts: Real-time trading software, $80/mo • Free portfolios with 75 symbols,news and more REACT TO THIS MEMBER • Add to favorite members (formerly membermark) • Ignore/Hide this poster in all boards • Report TOS violation